Protagonist Therapeutics (PTGX) Free Cash Flow (2015 - 2026)

Protagonist Therapeutics has disclosed Free Cash Flow across 12 years of filings, most recently posting -$49.2 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$49.2 million, down 139.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$118.4 million (down 135.28% YoY), and the FY2025 annual result was $56.1 million, down 69.32% from the prior year.
• Free Cash Flow came in at -$49.2 million for Q1 2026 at Protagonist Therapeutics, down from -$38.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $268.4 million in Q2 2024 to a low of -$49.2 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$27.5 million (2024), against an average of $584882.4.
• Peak annual rise in Free Cash Flow reached 1116.1% in 2024, while the deepest fall reached 278.31% in 2024.
• Protagonist Therapeutics' Free Cash Flow stood at -$31.7 million in 2022, then jumped by 153.43% to $16.9 million in 2023, then tumbled by 278.31% to -$30.2 million in 2024, then declined by 27.64% to -$38.6 million in 2025, then dropped by 27.49% to -$49.2 million in 2026.
• The last three Free Cash Flow figures came in at -$49.2 million (Q1 2026), -$38.6 million (Q4 2025), and -$587000.0 (Q3 2025), per Business Quant data.